Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
This is an open-label, dose escalation study to evaluate the safety, tolerability,
pharmacokinetics, and preliminary evidence of antitumor activity of CPO-100 administered
intravenously in cycles of 3 weekly doses with 1 week rest (1 cycle = 4 weeks) in adult
patients with advanced solid tumors. The second part of the study will further evaluate the
safety and tolerability of as well as antitumor activity at the recommended dose from the
dose escalation phase.